Flow-mediated dilation in patients with coronary artery disease is enhanced by high dose atorvastatin compared to combined low dose atorvastatin and ezetimibe: results of the CEZAR study.

M. Ostad,Silke Eggeling,P. Tschentscher,E. Schwedhelm,R. Böger,P. Wenzel,T. Meinertz,T. Munzel,A. Warnholtz

DOI: https://doi.org/10.1016/j.atherosclerosis.2008.11.032

IF: 5.3

2009-07-01

Atherosclerosis

Abstract:

What problem does this paper attempt to address?

Transcutaneous electrical nerve stimulation (TENS) for dementia.

M. Cameron,E. Lonergan,Helen Lee

DOI: https://doi.org/10.1002/14651858.CD004032

IF: 8.4

2003-07-21

Cochrane Database of Systematic Reviews

Abstract:BACKGROUND Transcutaneous electrical nerve stimulation (TENS) is the application of an electrical current through electrodes attached to the skin. The commonest clinical application of TENS is pain control. TENS is also used occasionally for the treatment of a range of neurological and psychiatric conditions including drug and alcohol dependence, headaches, and depression. TENS is rarely used for the treatment of dementia. However, since the early 1990s a number of studies carried out by a group in the Netherlands, and one study carried out by a group in Japan, suggest that TENS applied to the back or head may improve cognition and behaviour in patients with Alzheimer's disease or multi-infarct dementia. It was claimed that applying TENS could benefit patients with dementia by altering the activity of various neurotransmitters, or by increasing brain activity and thereby retarding neural degeneration and stimulating regenerative processes. It is claimed that application of TENS to the head may also alleviate the sleep disorders associated with dementia. OBJECTIVES The aim of this review is to determine the effectiveness and safety of transcutaneous electrical nerve stimulation (TENS) in the treatment of dementia. Secondary objectives of this review are to determine whether any effect of treatment of dementia with TENS is influenced by any treatment parameters or patient features, including: the duration of treatment, electrical waveform, current amplitude, pulse duration and frequency and the patient's type or severity of cognitive impairment. SEARCH STRATEGY The trials were identified from a search of the Specialized Register of the Cochrane Dementia and Cognitive Improvement Group on 10 December 2002 using the terms TENS, transcutaneous, "transcutaneous electrical nerve stimulation", and "electric stimulation". The CDCIG Specialized Register contains records from all major health care databases and many ongoing trials databases and is regularly updated. SELECTION CRITERIA All RCTs in which TENS was used as an intervention for people with dementia were included in this review. This included peripherally applied transcutaneous electrical stimulation as well as transcutaneous electrical stimulation applied to the head (also known as cranial electrical stimulation (CES)). DATA COLLECTION AND ANALYSIS All RCTs that fulfilled the inclusion criteria for the review and for which sufficient data were available were included in this meta-analysis. Two reviewers extracted the data from the included trials. All except one of the included trials used similar outcome measures. Data of the same outcome measures were combined for analysis. MAIN RESULTS Eight trials were included in the review but only 3 trials could be included in the meta-analysis. Sufficient data to include the other trials in the meta-analysis could not be obtained. From this limited analysis it appears that TENS produced a statistically significant improvement directly after treatment in: delayed recall of 8 words in one trial, face recognition in two trials and motivation in one trial however, no effect of TENS was found on any of the many other neuropsychological and behavioural measures evaluated either directly after TENS treatment or 6 weeks after treatment was completed. REVIEWER'S CONCLUSIONS Although a number of studies suggest that TENS may produce short lived improvements in some neuropsychological or behavioural aspects of dementia, the limited presentation and availability of data from these studies does not allow definite conclusions on the possible benefits of this intervention. Since most of the currently published studies are well designed, although the numbers of subjects in each study is small, analysis of the complete original data from these and/or future studies may allow more definitive conclusions to be drawn.
Time trends in reported diagnoses of childhood neuropsychiatric disorders: a Danish cohort study

Hjördís Osk Atladóttir,Erik T Parner,Diana Schendel,Søren Dalsgaard,Per Hove Thomsen,Poul Thorsen

DOI: https://doi.org/10.1001/archpedi.161.2.193

Abstract:Objectives: To examine trends in autism (autism spectrum disorder and childhood autism) in the context of 3 additional childhood neuropsychiatric disorders: hyperkinetic disorder, Tourette syndrome, and obsessive-compulsive disorder. Design: Population-based cohort study. Setting: Children were identified in the Danish Medical Birth Registry. Relevant outcomes were obtained via linkage with the Danish National Psychiatric Register, which included reported diagnoses through 2004 by psychiatrists using diagnostic criteria from the International Statistical Classification of Diseases, 10th Revision. Participants: All children born in Denmark from 1990 through 1999, a total of 669 995 children. Main outcome measures: Cumulative incidence proportion by age, stratified by year of birth, for each disorder. Results: Statistically significant increases were found in cumulative incidence across specific birth years for autism spectrum disorder, childhood autism, hyperkinetic disorder, and Tourette syndrome. No significant change in cumulative incidence was observed for obsessive-compulsive disorder. Conclusions: Recent increases in reported autism diagnoses might not be unique among childhood neuropsychiatric disorders and might be part of a more widespread epidemiologic phenomenon. The reasons for the observed common pattern of change in reported cumulative incidence could not be determined in this study, but the data underscore the growing awareness of and demand for services for children with neurodevelopmental disorders in general.
The increasing prevalence of reported diagnoses of childhood psychiatric disorders: a descriptive multinational comparison

Hjördis O Atladottir,David Gyllenberg,Amanda Langridge,Sven Sandin,Stefan N Hansen,Helen Leonard,Mika Gissler,Abraham Reichenberg,Diana E Schendel,Jenny Bourke,Christina M Hultman,Dorothy E Grice,Joseph D Buxbaum,Erik T Parner

DOI: https://doi.org/10.1007/s00787-014-0553-8

Abstract:The objective of this study is to compare the time trend of reported diagnoses of autism spectrum disorder (ASD), hyperkinetic disorder, Tourette's syndrome, and obsessive-compulsive disorder across four countries after standardizing the study period, diagnostic codes used to define the conditions and statistical analyses across countries. We use a population-based cohort, including all live-born children in Denmark, Finland, Sweden and Western Australia, from January 1, 1990, through December 31, 2007 and followed through December 31, 2011. The main outcome measure is age-specific prevalence of diagnoses reported to population-based registry systems in each country. We observe an increase in age-specific prevalence for reported diagnoses of all four disorders across birth-year cohorts in Denmark, Finland, Sweden, and (for ASD) Western Australia. Our results highlight the increase in the last 20 years in the number of children and families in contact with health care systems for diagnosis and services for an array of childhood neuropsychiatric disorders, a phenomenon not limited to ASD. Also, the age of diagnosis of the studied disorders was often much higher than what is known of the typical age of onset of symptoms, and we observe limited leveling off in the incidence rate with increasing age.
The incidence and prevalence of pervasive developmental disorders: a Danish population-based study

M B Lauritsen,C B Pedersen,P B Mortensen

DOI: https://doi.org/10.1017/s0033291704002387

Abstract:Background: Based on prevalence studies and the few incidence studies of pervasive developmental disorders (PDDs) the prevalence and incidence of these disorders have been claimed to be increasing. Method: The annual and age-specific prevalence and incidence rates of childhood autism, atypical autism, Asperger's disorder, and pervasive developmental disorder not otherwise specified (PDD-NOS) in Denmark during the period 1971--2000 in children younger than 10 years were estimated using data from the Danish Psychiatric Central Register. Results: A total of 2.4 million children younger than 10 years were followed and 2061 cases with the PDDs studied were identified. Generally, the prevalence and incidence rates of the PDDs studied were stable until the early 1990s after which an increase in the occurrence of all disorders was seen, until 2000. The annual incidence rate per 10000 children younger than 10 years was 2.0 for childhood autism, 0.7 for atypical autism, 1.4 for Asperger's disorder, and 3.0 for PDD-NOS in 2000. We calculated a 'corrected' prevalence of childhood autism at 11.8, atypical autism at 3.3, Asperger's disorder at 4.7, and PDD-NOS at 14.6 per 10,000 children younger than 10 years on 1 January 2001. Conclusions: We found that the estimated prevalences of the PDDs studied were probably underestimated. Furthermore, the increasing prevalence and incidence rates during the 1990s may well be explained by changes in the registration procedures and more awareness of the disorders, although a true increase in the incidence cannot be ruled out.
Prevalence of Parent-Reported Diagnosis of Autism Spectrum Disorder Among Children in the US, 2007

Michael D. Kogan,Stephen J. Blumberg,Laura A. Schieve,Coleen A. Boyle,James M. Perrin,Reem M. Ghandour,Gopal K. Singh,Bonnie B. Strickland,Edwin Trevathan,Peter C. van Dyck

DOI: https://doi.org/10.1542/peds.2009-1522

2009-11-01

PEDIATRICS

Abstract:OBJECTIVES: The reported increasing prevalence of autism spectrum disorder (ASD) and attendant health and family impact make monitoring of ASD prevalence a public health priority. METHODS: The prevalence of parent-reported diagnosis of ASD among US children aged 3 to 17 years was estimated from the 2007 National Survey of Children's Health (sample size: 78037). A child was considered to have ASD if a parent/guardian reported that a doctor or other health care provider had ever said that the child had ASD and that the child currently had the condition. The point-prevalence for ASD was calculated for those children meeting both criteria. We examined sociodemographic factors associated with current ASD and with a past (but not current) ASD diagnosis. The health care experiences for children in both ASD groups were explored. RESULTS: The weighted current ASD point-prevalence was 110 per 10,000. We estimate that 673,000 US children have ASD. Odds of having ASD were 4 times as large for boys than girls. Non-Hispanic (NH) black and multiracial children had lower odds of ASD than NH white children. Nearly 40% of those ever diagnosed with ASD did not currently have the condition; NH black children were more likely than NH white children to not have current ASD. Children in both ASD groups were less likely than children without ASD to receive care within a medical home. CONCLUSIONS: The observed point-prevalence is higher than previous US estimates. More inclusive survey questions, increased population awareness, and improved screening and identification by providers may partly explain this finding.

pediatrics
Short report: Transition to International Classification of Diseases, 10th Revision and the prevalence of autism in a cohort of healthcare systems

Musu M Sesay,Courtney E McCracken,Christine Stewart,Gregory Simon,Robert Penfold,Brian Ahmedani,Rebecca C Rossom,Christine Y Lu,Arne Beck,Karen J Coleman,Yihe Daida,Frances L Lynch,John Zeber,Laurel Copeland,Ashli Owen-Smith

DOI: https://doi.org/10.1177/13623613231220687

2024-01-21

Autism

Abstract:Autism, Ahead of Print. Currently, the prevalence of autism spectrum disorder (henceforth "autism") is 1 in 36, an increasing trend from previous estimates. In 2015, the United States adopted a new version (International Classification of Diseases, 10th Revision) of the World Health Organization coding system, a standard for classifying medical conditions. Our goal was to examine how the transition to this new coding system impacted autism diagnoses in 10 healthcare systems. We obtained information from electronic medical records and insurance claims data from July 2014 through December 2016 for each healthcare system. We used member enrollment data for 30 consecutive months to observe changes 15 months before and after adoption of the new coding system. Overall, the rates of autism per 1000 enrolled members was increasing for 0- to 5-year-olds before transition to International Classification of Diseases, 10th Revision and did not substantively change after the new coding was in place. There was variation observed in autism diagnoses before and after transition to International Classification of Diseases, 10th Revision for other age groups. The change to the new coding system did not meaningfully affect autism rates at the participating healthcare systems. The increase observed among 0- to 5-year-olds is likely indicative of an ongoing trend related to increases in screening for autism rather than a shift associated with the new coding.Lay abstractCurrently, the prevalence of autism spectrum disorder (henceforth "autism") is 1 in 36, an increasing trend from previous estimates. In 2015, the United States adopted a new version (International Classification of Diseases, 10th Revision) of the World Health Organization coding system, a standard for classifying medical conditions. Our goal was to examine how the transition to this new coding system impacted autism diagnoses in 10 healthcare systems. We obtained information from electronic medical records and insurance claims data from July 2014 through December 2016 for each healthcare system. We used member enrollment data for 30 consecutive months to observe changes 15 months before and after adoption of the new coding system. Overall, the rates of autism per 1000 enrolled members was increasing for 0- to 5-year-olds before transition to International Classification of Diseases, 10th Revision and did not substantively change after the new coding was in place. There was variation observed in autism diagnoses before and after transition to International Classification of Diseases, 10th Revision for other age groups. The change to the new coding system did not meaningfully affect autism rates at the participating healthcare systems. The increase observed among 0- to 5-year-olds is likely indicative of an ongoing trend related to increases in screening for autism rather than a shift associated with the new coding.

psychology, developmental
Secular changes in the symptom level of clinically diagnosed autism

Olof Arvidsson,Christopher Gillberg,Paul Lichtenstein,Sebastian Lundström

DOI: https://doi.org/10.1111/jcpp.12864

Abstract:Background: The prevalence of autism has been reported to have increased worldwide. A decrease over time in the number of autism symptoms required for a clinical autism diagnosis would partly help explain this increase. This study aimed to determine whether the symptom level of clinically diagnosed autism cases below age 13 had changed over time. Methods: Parents of Swedish 9-year old twins (n = 28,118) participated in a telephone survey, in which symptoms and dysfunction/suffering related to neurodevelopmental disorders [including autism, but also attention-deficit/hyperactivity disorder (ADHD), Developmental Coordination Disorder (DCD), and Learning Disabilities (LD)] in their children were assessed over a 10-year period. Survey data was merged with the National Patient Register containing clinically registered autism diagnoses (n = 271). Results: In individuals who had been clinically diagnosed with autism before the age of 13, the symptom score for autism decreased on average 30% over more than a decade in birth cohorts 1992-2002. There was an average decrease of 50% in the autism symptom score from 2004 to 2014 in individuals who were diagnosed with autism at ages 7-12, but there was no decrease in those diagnosed at ages 0-6. Conclusions: Over time, considerably fewer autism symptoms seemed to be required for a clinical diagnosis of autism, at least for those diagnosed after the preschool years. The findings add support for the notion that the observed increase in autism diagnoses is, at least partly, the by-product of changes in clinical practice, and flag up the need for working in agreement with best practice guidelines.
The effects of a back rehabilitation programme for patients with chronic low back pain.

L. Gaskell,S. Enright,S. Tyson

DOI: https://doi.org/10.1111/J.1365-2753.2006.00772.X

2007-10-01

Journal of Evaluation in Clinical Practice

Abstract:AIM The aim of this paper was to perform a pragmatic before-after analysis of a back rehabilitation programme (BRP) for patients with chronic low back pain (LBP). A total of 877 patients were recruited onto the BRP, which were carried out at four centres within the Wrightington, Wigan and Leigh NHS Trust. The BRP consisted of nine 2-hour group sessions of therapy run over 5 weeks and included 1 hour of exercise and 1 hour of education, advice problem solving and goal setting. METHOD Using the Wilcoxen signed rank tests and paired t-tests levels of pain, disability, anxiety and depression were significantly reduced pre-post programme (P < 0.001). In addition, the levels of fitness and perceived control improved significantly (P < 0.001) suggesting that participants were better able to manage their LBP. CONCLUSION Overall, the BRP proved to be effective in reducing pain, disability, anxiety and depression levels for people with chronic LBP. However, despite significant improvements in outcome measures only 50% of the patients completed the BRP and questionnaires post BRP. The implications of the findings are discussed with respect to modified programmes and alternative management for patients within different subgroups of LBP.
Direct radioimmunoassay of cortisol in saliva and its application to the dexamethasone suppression test in affective disorders

K. Hanada,N. Yamada,K. Shimoda,Kiyohisa Takahashi,Saburo Takahashi

DOI: https://doi.org/10.1016/0306-4530(85)90057-5

IF: 4.693

1985-12-31

Psychoneuroendocrinology

Abstract:
Gestational Age and Autism Spectrum Disorder: Trends in Risk Over Time

H Ó Atladóttir,D E Schendel,T B Henriksen,L Hjort,E T Parner

DOI: https://doi.org/10.1002/aur.1525

Abstract:Autism Spectrum Disorder (ASD) is a serious neurodevelopmental disorder. Several previous studies have identified preterm birth as a risk factor for ASD but none has studied whether the association between gestational age and ASD has changed over time. This is a Danish population-based follow-up study including live-born singletons born in Denmark between 1980 and 2009, identified in the Danish Medical Birth Registry, a study population of 1,775,397 children. We used a Cox regression model combined with spline to study the risk for ASD by gestational age across three decades of birth cohorts. We included 19,020 children diagnosed with ASD. Across all birth year cohorts, we found that the risk of being diagnosed with ASD increased with lower gestational age (P-value: <0.01). Across all gestational weeks, we found a statistically significant higher risk estimates in birth cohort 1980 to 1989, compared to birth cohorts 1990 to 1999 and 2000 to 2009, respectively. No statistically significant difference in risk estimates was observed between birth cohort 1990 to 1999 and 2000 to 2009. The observed time trend in risk of ASD after preterm birth may reflect: (1) a change in the risk profile of persons with ASD due to the broadening of ASD diagnostic criteria over time; or (2) improved neonatal care for low GA infants, which has reduced risk of adverse outcomes like ASD in preterm children.
Error in Source Data for Prevalence of Autism Spectrum Disorder

Guoqing Xu,Lane Strathearn,Buyun Liu,Wei Bao

DOI: https://doi.org/10.1001/jama.2018.0022

IF: 11.816

2018-01-01

JAMA

Abstract:Using data from the National Health Interview Survey (NHIS), we found that the weighted prevalence of autism spectrum disorder (ASD) was 2.41% (95% CI, 2.17%-2.65%) in 2014-2016.Sample weights are provided with the NHIS data for researchers to use during analysis to take into account unequal probabilities of selection and nonresponse.For the analysis of the 2016 data, we used the weights originally released by the Centers for Disease Control and Prevention (CDC) in June 2017.The CDC identified inaccuracies in the original sampling weights and updated them in November 2017, after acceptance of the Research Letter, but we did not become aware of this change until December 27, 2017.We reran all the analyses for our estimates using the updated weights.The conclusions were not changed, but there were some small changes in the results for the 2016 data and the pooled data from 2014-2016.For example, the overall prevalence of ASD changed from 2.41% to 2.47% (95% CI, 2.20%-2.73%),with the estimate being within the original 95% CI.
Behavioral and neurochemical changes in response to acute stressors: Influence of previous chronic exposure to immobilization

O. Pol,Ll. Campmany,M. Gil,A. Armario

DOI: https://doi.org/10.1016/0091-3057(92)90133-Z

1992-07-01

Abstract:
Animal Models for Studying Respiratory Syncytial Virus Infection and Its Long Term Effects on Lung Function

J. Domachowske,C. Bonville,H. Rosenberg

DOI: https://doi.org/10.1097/01.inf.0000144672.81955.a4

2004-11-01

The Pediatric Infectious Disease Journal

Abstract:Background: Human respiratory syncytial virus (hRSV) infection causes a spectrum of illnesses ranging from mild infection to life-threatening bronchiolitis and respiratory failure. Human studies on the pathogenesis of RSV infection are invaluable, but animal models permit advances with the use of experimental strategies that would be inappropriate in human studies. Methods: We review the advantages and disadvantages of various animal models for the study of hRSV infection. Results: No animal model of hRSV infection replicates the complete spectrum of disease severity seen in humans. Available models differ in their ability to incorporate genetic technology and to allow the study of immunity, vaccine efficacy and treatment interventions. Although hRSV establishes disease in primates, this advantage is outweighed by the impracticalities and cost of using such models. The study of bovine RSV infection in calves is appealing because of parallels with human disease. Among rodent models, BALB/c mice have helped delineate the mechanisms underlying vaccine-enhanced RSV disease, and cotton rats have been used for preclinical testing. The single major disadvantage of studying hRSV in rodent models is the limited extent to which this host-restricted human pneumovirus replicates in mouse lung tissue. The rodent-specific Pneumovirus pathogen, pneumonia virus of mice, causes an infection that mirrors severe bronchiolitis and pneumonia in infants infected with RSV, including robust virus replication with profound inflammation. Conclusion: The recent development of the pneumonia virus of mice model has permitted exploration of the mechanisms of severe Pneumovirus disease in vivo with the use of sophisticated genetic tools and genetically manipulated mouse strains.
Understanding autism diagnosis in primary care: Rates of diagnosis from 2004 to 2019 and child age at diagnosis

Jessica V Smith,Michelle Menezes,Sophie Brunt,Jessica Pappagianopoulos,Eleonora Sadikova,Micah O Mazurek

DOI: https://doi.org/10.1177/13623613241236112

2024-03-10

Autism

Abstract:Autism, Ahead of Print. The capacity of the workforce lags behind the current demand for timely autism diagnostic assessment. Primary care providers (PCPs) are well-positioned to diagnose autism at earlier ages than providers from other disciplines. Thus, bolstering PCPs' diagnostic capabilities has been the focus of many recent capacity-building initiatives. Using data from the National Survey of Children's Health, this study aimed to evaluate whether diagnosis of autism in primary care has changed over time and whether diagnosis in primary care relates to age at autism diagnosis. Results indicated that the likelihood of being diagnosed with autism by a PCP decreased by about 2% with every passing year from 2004 to 2019 when controlling for demographic characteristics. PCPs diagnosed children approximately 1 year earlier than non-PCPs (e.g., psychiatrists and psychologists), which supports the critical role PCPs can play in timely diagnosis. Further research is needed to understand why the proportion of children diagnosed by PCPs has decreased over time; however, these findings suggest that capacity-building initiatives have not yet reached community practice. Future research should focus on the dissemination and implementation of training initiatives in community-based primary care practices.Lay abstractThe current demand for autism diagnostic services exceeds the ability of the workforce to assess and diagnose children in a timely manner. One solution may be to equip primary care providers (PCPs) with the tools and expertise needed to diagnose autism within their practice. PCPs are often trusted professionals who have many touchpoints with children during early development, in which they can identify early signs of autism. Recent initiatives have focused on bolstering PCPs' diagnostic capabilities; however, no studies have examined how the rates of autism diagnosis in primary care have changed over time. We aimed to evaluate whether autism diagnosis in primary care has changed over time and how diagnosis in primary care relates to a child's age at the time of diagnosis. We found that the likelihood of a child being diagnosed by a PCP decreased by about 2% with every passing year from 2004 to 2019 when accounting for demographic characteristics. In our sample, PCPs diagnosed children approximately 1 year earlier than non-PCPs (e.g., psychologists and psychiatrists). Further research is needed to understand why the proportion of children diagnosed by PCPs decreases over time. However, this decrease suggests more work is needed to get capacity-building initiatives into community primary care practice. Though we must continue to find effective ways to build community PCPs' ability to diagnose autism, the present findings support the crucial role PCPs can play in early autism diagnosis.

psychology, developmental
Diagnosis despite clinical ambiguity: physicians' perspectives on the rise in Autism Spectrum disorder incidence

Michael Davidovitch,Dorit Shmueli,Ran Shmuel Rotem,Aviva Mimouni Bloch

DOI: https://doi.org/10.1186/s12888-021-03151-z

IF: 4.144

2021-03-12

BMC Psychiatry

Abstract:Background: To provide insight on physicians' perspectives concerning recent changes in the incidence and diagnostic process of Autism Spectrum Disorder (ASD) compared to other mental and neurodevelopmental disorders. Method: A questionnaire was sent to 191 specialists in child neurology and child development, and 200 child psychiatrists in Israel. Information was collected on professional background, as well as on physicians' opinions concerning the accuracy and rate of ASD diagnosis compared to that of cerebral palsy (CP), mental illness, and Attention Deficit Hyperactivity Disorder (ADHD). For each closed-ended question, a global chi-square test for categorical variables was performed. Results: 115 (60.2%) of specialists in child neurology and development, and 59 (29.5%) of child psychiatrists responded. Most physicians (67.2%) indicated that there was a moderate/significant increase in the incidence of ASD, which was higher than similar responses provided for CP (2.9%, p < 0.01) and mental illnesses (14.4%, p < 0.01), and similar to responses provided for ADHD (70.1%, p = 0.56). 52.8% of physicians believed that in more than 10% of clinical assessments, an ASD diagnosis was given despite an inconclusive evaluation (CP: 8.6%, p < 0.01; mental illnesses: 25.8%, p = 0.03; ADHD: 68.4%, p = 0.03). Conclusion: The clinicians perceive both ASD and ADHD as over-diagnosed disorders. The shared symptomology between ASD and other disorders, coupled with heightened awareness and public de-stigmatization of ASD and with the availability of ASD-specific services that are not accessible to children diagnosed with other conditions, might lead clinicians to over-diagnose ASD. It is advisable to adopt an approach in which eligibility for treatments is conditional on function, rather than solely on a diagnosis. The medical community should strive for accurate diagnoses and a continuous review of diagnostic criteria.
Topical application of a novel immunomodulatory peptide, RDP58, reduces skin inflammation in the phorbol ester-induced dermatitis model.

Christopher G De Vry,M. Valdez,M. Lazarov,E. Muhr,R. Buelow,T. Fong,S. Iyer

DOI: https://doi.org/10.1111/J.0022-202X.2005.23831.X

IF: 7.59

2005-09-01

Journal of Investigative Dermatology

Abstract:RDP58 is the first lead compound in a series of immunomodulating decapeptides discovered through activity-based screening and computer-aided, rational design. RDP58 disrupts cellular responses signaled through the Toll-like and tumor necrosis factor (TNF) receptor families and occludes important signal transduction pathways involved in inflammation, inhibiting the production of tumor necrosis factor alpha (TNFalpha), interferon-gamma, interleukin (IL)-2, IL-6, and IL-12. These pro-inflammatory cytokines are thought to be involved in the pathogenesis of several inflammatory and autoimmune diseases, including atopic dermatitis and psoriasis. The goal of this study was to determine the ability of RDP58 to inhibit skin inflammation following exposure to the well-characterized protein kinase C activator and tumor promoter 12-O-tetradecanoylphorbol-13-acetate (TPA). Topical application of RDP58 to the epidermis following TPA treatment resulted in the amelioration of the phorbol ester-induced irritant contact dermatitis. Substantial reductions were observed in skin thickness and tissue weight, neutrophil-mediated myeloperoxidase activity, inflammatory cytokine production, and various histopathological indicators. We also found RDP58 to be effective in reducing the compounding inflammatory damage brought on by chronic TPA exposure, and that it is capable of targeting inflammatory mediators specifically in the keratinocyte. These results demonstrate that topically applied RDP58 is an effective anti-inflammatory treatment in the phorbol ester-induced dermatitis model, and suggest that it may have therapeutic potential in a variety of immune-related cutaneous diseases.
Arylzinc alkoxides: [ArZnOCHPr(i)2]2 and Ar2Zn3(OCHPr(i)2)4 when Ar = C6H5, p-CF3C6H4, 2,4,6-Me3C6H2, and C6F5.

M. Chisholm,J. Gallucci,Hongfeng Yin,Hongshi Zhen

DOI: https://doi.org/10.1021/IC048332I

IF: 4.6

2005-05-25

Inorganic Chemistry

Abstract:From the reactions between diarylzinc compounds (Ar2Zn) and the alcohol (Pr(i)2CHOH) in toluene, the compounds [ArZn(OCHPr(i)2)]2 (Ar = C6H5, C6F5, p-CF3C6H4, and 2,4,6-Me3C6H2) have been isolated and shown to exist in equilibra with the trinuclear complexes Ar2Zn3(OCHPr(i)2)4 and Ar2Zn when Ar = C6H5, C6F5, and p-CF3C6H4. The trinuclear complexes have also been prepared from reactions of the Ar2Zn compounds with the alcohol, which reveals that the ease of Zn-C(aryl) bond cleavage is sensitive to the nature of the Ar group: C6H5 > 4-CF3C6H4 > C6F5. The molecular structures of Ar2Zn3(OCHPr(i)2)4 where Ar = p-CF3C6H4 and C6F5 and [ArZn(OCHPr(i)2)]2 where Ar = C6F5, p-CF3C6H4, and 2,4,6-Me3C6H2 are reported based on single-crystal X-ray diffraction studies. The X-ray structure of Zn(p-CF3C6H4)2 is also reported. The reactivity of these new compounds toward the polymerization of propylene oxide (PO) and the copolymerization of PO and CO2 have been investigated along with related reactions involving the partial hydrolysis of the Ar2Zn and R2Zn compounds, where R = t-Bu, n-Bu, and n-Oct. These results are compared with the previous studies employing Et2Zn as an organozinc precursor.
Neoadjuvant chemoradiotherapy with cisplatin plus vinorelbine versus cisplatin plus fluorouracil for esophageal squamous cell carcinoma: A matched case-control study.

Shiliang Liu,Hong Yang,Peng Zhang,Li Zhang,Lei Zhao,Liling Luo,J. Fu,Mengzhong Liu,M. Xi

DOI: https://doi.org/10.1016/j.radonc.2015.07.020

IF: 6.901

2015-08-01

Radiotherapy and Oncology

Abstract:
Prevalence of Autism in Scandinavian Countries (Denmark, Norway, Sweden), and Nordic Countries (Finland, Iceland, the Faroe Islands, and Greenland)

Kristine Jensen de López,Heidi Thirup Møller

DOI: https://doi.org/10.2147/ndt.s466081

IF: 2.989

2024-08-20

Neuropsychiatric Disease and Treatment

Abstract:Kristine M Jensen de López, Heidi Thirup Møller Department of Communication and Psychology, Center for Developmental & Applied Psychological Science, Aalborg University, Aalborg, Denmark Correspondence: Kristine M Jensen de López, Email Aim: This study aims to identify and describe prevalence rates for ASD in the Scandinavian countries (Denmark, Norway, Sweden), as well as the Nordic countries (Finland, Iceland, the Faroe Islands, and Greenland). Methods: A systematic review was conducted following PRISMA (2009) guidelines and based on the two databases: APA PsycINFO and MEDLINE (PubMed). Results: A total of 13 studies were included in the analyses. It was not possible to identify ASD prevalence studies for Greenland. However, for the remaining countries descriptive increases in ASD prevalence figures were observed. Increases were evident both in relation to age and birth cohort. Studies varied regarding which age group and cohort prevalence figures were reported. The most reported age group was the 7– 12-year-olds. In this group, recent prevalence figures for Denmark ranged from 0.26% to 1.47%, in Norway 0.6%, in Sweden 0.23– 0.68%, in Finland 0.22– 0.86%, and in Iceland 2.40– 3.13%. Iceland stood out in terms of higher prevalence figures compared to the other Scandinavian and Nordic countries. Two studies from the Faroe Islands reported ASD prevalence rates between 0.50% and 0.94% for 7– 24-year-olds. These studies were based on nationwide figures, but not from national or official registers. Discussion and conclusion: This study documented increasing prevalence of ASD in Scandinavian and Nordic countries. Several explanations of aspects that may contribute to the increases were discussed, eg, heightened awareness of ASD and earlier diagnosis. The importance of considering differences in data sources was discussed, with an emphasis on the importance of using national registries when available as this source is the most reliable and valid. The absence of prevalence figures for Greenland may be attributed to structural as well as cultural aspects, eg, two parallel systems assessing ASD, cultural taboos as well as lack of awareness of ASD. Suggestions or how to gain knowledge on ASD prevalence in Greenland is presented. Keywords: autism spectrum disorder, prevalence, Scandinavia, Nordic Autism spectrum disorder (ASD) is a lifelong neurodevelopmental condition. 1 In accordance with the diagnostic criteria, individuals with ASD experience three behavioural disturbances consisting of social abilities, language impairment, and stereotyped, repetitive patterns of behaviour. 2 The description of ASD in The International Classification of Diseases and Related Health Problems 11th edition is as follows: Autism spectrum disorder is characterised by persistent deficits in the ability to initiate and to sustain reciprocal social interaction and social communication, and by a range of restricted, repetitive, and inflexible patterns of behaviour, interests or activities that are clearly atypical or excessive for the individual's age and sociocultural context. 3 Although ASD is influenced by genetic factors, the precise biological implications are still being debated. 4 Genetic explanations are supported by twin and family studies. 2,5,6 ASD is predominantly defined through behavioural assessment and is therefore often referred to as a behavioural diagnosis. The limitations of assessing psychiatric disorders through behaviour are that members of the respective diagnostic group often show high levels of heterogeneity as different individuals are affected to different degrees. 4 Hence, making a generalization about the experiences of individuals living with ASD is challenging 7 and recent attempts have been to evaluate ASD as a spectrum disorder. The large heterogeneity is also a challenge in research investigating the disorder 8 and hinders precise prognostic explanations for parents, given the wide spectrum of potential lifelong challenges of ASD. ASD is more prevalent in males than females. 9 While some individuals with ASD can live without significant support in adult life, others may never acquire a functional language or be able to develop interpersonal relationships. The understanding of ASD has evolved over the years. It is now 80 years since Leo Kanner first described infantile autism in 1943, and it took nearly 40 years for the diagnosis to receive an official recognition. Since then, the ASD diagnosis has undergone several changes, with both the description of the diagnosis and the terminology changing over time. 10 This is reflected in the two main official manuals for diagnosing mental disorders: The Int -Abstract Truncated-

psychiatry,clinical neurology
Incidence, prevalence, and global burden of autism spectrum disorder from 1990 to 2019 across 204 countries

Marco Solmi,Minjin Song,Dong Keon Yon,Seung Won Lee,Eric Fombonne,Min Seo Kim,Seoyeon Park,Min Ho Lee,Jimin Hwang,Roberto Keller,Ai Koyanagi,Louis Jacob,Elena Dragioti,Lee Smith,Christoph U. Correll,Paolo Fusar-Poli,Giovanni Croatto,Andre F. Carvalho,Jae Won Oh,San Lee,Corentin J. Gosling,Keun-Ah Cheon,Dimitris Mavridis,Che-Sheng Chu,Chih-Sung Liang,Joaquim Radua,Laurent Boyer,Guillaume Fond,Jae Il Shin,Samuele Cortese

DOI: https://doi.org/10.1038/s41380-022-01630-7

IF: 11

2022-06-30

Molecular Psychiatry

Abstract:Autism spectrum disorder (ASD) substantially contributes to the burden of mental disorders. Improved awareness and changes in diagnostic criteria of ASD may have influenced the diagnostic rates of ASD. However, while data on trends in diagnostic rates in some individual countries have been published, updated estimates of diagnostic rate trends and ASD-related disability at the global level are lacking. Here, we used the Global Burden of Diseases, Injuries, and Risk Factors Study data to address this gap, focusing on changes in prevalence, incidence, and disability-adjusted life years (DALYs) of ASD across the world. From 1990 to 2019, overall age-standardized estimates remained stable globally. Both prevalence and DALYs increased in countries with high socio-demographic index (SDI). However, the age-standardized incidence decreased in some low SDI countries, indicating a need to improve awareness. The male/female ratio decreased between 1990 and 2019, possibly accounted for by increasing clinical attention to ASD in females. Our results suggest that ASD detection in low SDI countries is suboptimal, and that ASD prevention/treatment in countries with high SDI should be improved, considering the increasing prevalence of the disorder. Additionally, growing attention is being paid to ASD diagnosis in females, who might have been left behind by ASD epidemiologic and clinical research previously. ASD burden estimates are underestimated as GBD does not account for mortality in ASD.

biochemistry & molecular biology,neurosciences,psychiatry

Flow-mediated dilation in patients with coronary artery disease is enhanced by high dose atorvastatin compared to combined low dose atorvastatin and ezetimibe: results of the CEZAR study.

Transcutaneous electrical nerve stimulation (TENS) for dementia.

Time trends in reported diagnoses of childhood neuropsychiatric disorders: a Danish cohort study

The increasing prevalence of reported diagnoses of childhood psychiatric disorders: a descriptive multinational comparison

The incidence and prevalence of pervasive developmental disorders: a Danish population-based study

Prevalence of Parent-Reported Diagnosis of Autism Spectrum Disorder Among Children in the US, 2007

Short report: Transition to International Classification of Diseases, 10th Revision and the prevalence of autism in a cohort of healthcare systems

Secular changes in the symptom level of clinically diagnosed autism

The effects of a back rehabilitation programme for patients with chronic low back pain.

Direct radioimmunoassay of cortisol in saliva and its application to the dexamethasone suppression test in affective disorders

Gestational Age and Autism Spectrum Disorder: Trends in Risk Over Time

Error in Source Data for Prevalence of Autism Spectrum Disorder

Behavioral and neurochemical changes in response to acute stressors: Influence of previous chronic exposure to immobilization

Animal Models for Studying Respiratory Syncytial Virus Infection and Its Long Term Effects on Lung Function

Understanding autism diagnosis in primary care: Rates of diagnosis from 2004 to 2019 and child age at diagnosis

Diagnosis despite clinical ambiguity: physicians' perspectives on the rise in Autism Spectrum disorder incidence

Topical application of a novel immunomodulatory peptide, RDP58, reduces skin inflammation in the phorbol ester-induced dermatitis model.

Arylzinc alkoxides: [ArZnOCHPr(i)2]2 and Ar2Zn3(OCHPr(i)2)4 when Ar = C6H5, p-CF3C6H4, 2,4,6-Me3C6H2, and C6F5.

Neoadjuvant chemoradiotherapy with cisplatin plus vinorelbine versus cisplatin plus fluorouracil for esophageal squamous cell carcinoma: A matched case-control study.

Prevalence of Autism in Scandinavian Countries (Denmark, Norway, Sweden), and Nordic Countries (Finland, Iceland, the Faroe Islands, and Greenland)

Incidence, prevalence, and global burden of autism spectrum disorder from 1990 to 2019 across 204 countries